Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments

References

• Pu M, Chen J, Tao Z, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci. 2019;76:441–451.
   PubMed Web of Science ®Google Scholar
• Guan P, Yin Z, Li X, et al. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res. 2012;31:54.
   PubMed Web of Science ®Google Scholar
• To KK, Tong CW, Wu M, et al. MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside. World J Gastroenterol. 2018;24:2949–2973.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–222.
   PubMed Web of Science ®Google Scholar
• Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10:478.
   PubMed Web of Science ®Google Scholar
• Cheng CJ, Bahal R, Babar IA, et al. MicroRNA silencing for cancer therapy targeted to the tumor microenvironment. Nature. 2015;518:107–110.
   PubMed Web of Science ®Google Scholar
• Workman P, Al-Lazikani B, Clarke PA. Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr Opin Pharmacol. 2013;13:486–496.
   PubMed Web of Science ®Google Scholar
• Hosseinahli N, Agjapour M, Duijf PHG, et al. Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 2018;233:5574–5588.
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685–689.
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systematically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008;36:1153–1162.
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452:896–899.
   PubMed Web of Science ®Google Scholar
• Ghasabi M, Mansoori B, Mohammadi A, et al. MicroRNAs in cancer drug resistance: basic evidence and clinical applications. J Cell Physiol. 2019;234:2152–2168.
   PubMed Web of Science ®Google Scholar
• Petrovic N, Ergun S. MiRNAs as potential treatment targets and treatment options in cancer. Mol Diagn Ther. 2018;22:157–168.
   PubMed Web of Science ®Google Scholar
• Shah MY, Ferrajoli A, Sood AK, et al. MicroRNA therapeutics in cancer – an emerging concept. EBioMedicine. 2016;12:34–42.
   PubMed Web of Science ®Google Scholar
• Tyagi N, Arora S, Deshmukh SK, et al. Exploiting nanotechnology for the development of microRNA-based RNA therapeutics. J Biomed Nanotechnol. 2016;12:28–42.
   PubMed Web of Science ®Google Scholar
• Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010;70:7027–7030.
   PubMed Web of Science ®Google Scholar
• Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol. 2013;31:577.
   PubMed Web of Science ®Google Scholar
• Lagana A, Acunzo M, Romano G, et al. miR-Synth: A computational resources for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Res. 2014;42:5416–5425.
   PubMed Web of Science ®Google Scholar
• Acunzo M, Romano G, Nigita G, et al. Selective targeting of point-mutated KRAS through artificial microRNAs. Proc Natl Acad Sci USA. 2017;114:E4203–E4212.
   PubMed Web of Science ®Google Scholar
• Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet. 2009;67:29–60.
   PubMed Web of Science ®Google Scholar
• Liu W, Lv C, Zhang B, et al. MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression. RNA. 2017;23:1019–1027.
   PubMed Web of Science ®Google Scholar
• Zhang HD, Jiang LH, Sun DW, et al. miR-30a inhibits the biological function of breast cancer cells by targeting Notch1. Int J Mol Med. 2017;40:1235–1242.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Kelnar K, Stahlhut C, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2015;34:3547–3555.
   PubMed Web of Science ®Google Scholar
• Feng SD, Mao Z, Liu C, et al. Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma. Onco Targets Ther. 2017;10:5591–5604.
   PubMed Web of Science ®Google Scholar
• Han Z, Zhang Y, Yang Q, et al. miR-497 and miR-34a retard lung cancer growth by co-inhibiting cyclin E1 (CCNE1). Oncotarget. 2015;6:13149–13163.
   PubMedGoogle Scholar
• Cheng H, Xue J, Yang S, et al. Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development. Oncotarget. 2017;8:47984–47997.
   PubMedGoogle Scholar
• Yang Y, Li F, Saha MN, et al. miR-137 and miR197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma. Clin Cancer Res. 2015;21:2399–2411.
   PubMed Web of Science ®Google Scholar
• Su J, Liang H, Yao W, et al. miR-1443 and miR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS One. 2014;9:e114420.
   PubMed Web of Science ®Google Scholar
• Li H, Xing C, Zhou B, et al. A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. Exp Hematol. 2018;61:59–68.
   PubMed Web of Science ®Google Scholar
• Ferino A, Miglietta G, Picco R, et al. MicroRNA therapeutics: design of single-stranded miR-216b mimics to target KRAS in pancreatic cancer cells. RNA Biol. 2018;15:1273–1285.
   PubMed Web of Science ®Google Scholar
• Wang C, Su K, Zhang Y, et al. MicroRNA-365 targets multiple oncogenes to inhibit proliferation, invasion, and self-renewal aggressive endometrial cancer cells. Cancer Manag Res. 2018;10:5171–5185.
   PubMed Web of Science ®Google Scholar
• Koo KH, Kwon H. MicroRNA miR-4779 suppresss tumor growth by inducing apoptosis and cell cycle arrest through direct targeting of PAK2 and CCND3. Cell Death Dis. 2018;9:77.
   PubMed Web of Science ®Google Scholar
• Scherr M, Venturini L, Battmer K, et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 2007;35:e149.
   PubMed Web of Science ®Google Scholar
• Haraguchi T, Ozaki Y, Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009;37:e43.
   PubMed Web of Science ®Google Scholar
• Nguyen DD, Chang S. Development of novel therapeutic agents by inhibition of oncogenic microRNAs. Int J Mol Sci. 2017;19:E65.
   PubMed Web of Science ®Google Scholar
• Lennox KA, Behlke MA. A direct comparison of anti-microRNA oligonucleotide potency. Pharm Res. 2010;27:1788–1799.
   PubMed Web of Science ®Google Scholar
• Watts JK. Locked nucleic acid: tighter is different. Chem Commun. 2013;49:5618–5620.
   PubMed Web of Science ®Google Scholar
• Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44:6518–6548.
   PubMed Web of Science ®Google Scholar
• Miroshnichenko SK, Patutina OA, Burakova EA, et al. Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties. Proc Natl Acad Sci USA. 2019;116:1229–1234.
   PubMed Web of Science ®Google Scholar
• Lima JF, Cergueira L, Figueiredo C, et al. Anti-miRNA oligonucleotides: A comprehensive guide for design. RNA Biol. 2018;15:338–352.
   PubMed Web of Science ®Google Scholar
• Kim DG, Kim KH, Seo YJ, et al. Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy. Oncotarget. 2016;7:29400–29411.
   PubMedGoogle Scholar
• Zeniya S, Kuwahara H, Daizo K, et al. Agubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system. J Control Release. 2018;283:126–134.
   PubMed Web of Science ®Google Scholar
• Evers MM, Toonen LJ, van Roon-mon WM. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev. 2015;87:90–103.
   PubMed Web of Science ®Google Scholar
• Teplyuk NM, Uhlmann EJ, Gabriely G, et al. Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic. EMBO Mol Med. 2016;8:268–287.
   PubMed Web of Science ®Google Scholar
• Nedaeinia R, Sharifi M, Avan A, et al. Locked nucleic acid anti-miR-21 inihibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach. Cancer Gene Ther. 2016;23:246–253.
   PubMed Web of Science ®Google Scholar
• Lee TJ, Yoo JY, Shu D, et al. RNA nanoparticle-based targeted therapy for glioblastoma through inhibition of oncogenic miR-21. Mol Ther. 2017;25:1544–1555.
   PubMed Web of Science ®Google Scholar
• Liu Q, Wang D, Yuan M, et al. Capturing intracellular oncogenic microRNAs with self-assembled DNA nanostructures for microRNA-based cancer therapy. Chem Sci. 2018;9:7562–7568.
   PubMed Web of Science ®Google Scholar
• Lee SH, Jung YD, Choi YS, et al. Targeting of RUNX3 by miR-130a and miR-495 cooperatively increases cell proliferation and tumor angiogenesis in gastric cancer cells. Oncotarget. 2015;6:33269–33278.
   PubMedGoogle Scholar
• Naseri Z, Oskuee RK, Jaafari MR, et al. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. Int J Nanomedicine. 2018;13:7727–7747.
   PubMed Web of Science ®Google Scholar
• Seto AG, Beathy X, Lynch JM, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018;183:428–444.
   PubMed Web of Science ®Google Scholar
• Brognara E, Fabbri E, Montagner G, et al. High levels of apoptosis are induced in human glioma cells by co-administration of peptide nucleic acids targeting miR-221 and miR-222. Int J Oncol. 2016;48:1029–1038.
   PubMed Web of Science ®Google Scholar
• Cai B, Chen W, Pan Y, et al. Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer. Prostate. 2017;77:1057–1065.
   PubMed Web of Science ®Google Scholar
• Das DK, Persaud L, Sauane M. MicroRNA-4719 and microRNA-6756-5p correlate with castration-resistant prostate cancer progression through interleukin-24 regulation. Noncoding RNA. 2019;5:E10.
   PubMedGoogle Scholar
• Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4:721–726.
   PubMed Web of Science ®Google Scholar
• Liu S, Sun X, Wang M, et al. A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFkB and STAT3 in colorectal cancer cells. Gastroenterology. 2014;147:847–859.
   PubMed Web of Science ®Google Scholar
• Mignacca L, Saint-Germain E, Bernoit A, et al. Sponges against miR-19 and miR-155 reactivate p53-Socs-1 axis in hematopoietic cancers. Cytokine. 2016;82:80–86.
   PubMed Web of Science ®Google Scholar
• Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12:247–256.
   PubMed Web of Science ®Google Scholar
• Morgan MA, Schambach A. Engineering CAR-T cells for improved function against solid tumors. Front Immunol. 2018;9:2493.
   PubMed Web of Science ®Google Scholar
• Gentner B, Naldini L. Exploiting microRNA regulation for genetic engineering. Tissue Antigens. 2012;80:393–403.
   PubMedGoogle Scholar
• Wang Z. The principles of miRNA-masking antisense oligonucleotides technology. Methods Mol Biol. 2011;676:43–49.
   PubMedGoogle Scholar
• Kim K, Madak-Erdogan Z, Ventrella R, et al. A microRNA-196a2* and TP63 circuit regulated by estrogen receptor-a and ERK2 that controls breast cancer proliferation and invasiveness properties. Horm Cancer. 2013;4:78–91.
   PubMed Web of Science ®Google Scholar
• Drago-Ferrante R, Pentimalli F, Carlisi D, et al. Suppressive role exerted by miRNA-29-b-1-5p in triple negative breast cancer through SPIN1 regulation. Oncotarget. 2017;8:28939–28958.
   PubMedGoogle Scholar
• Munoz JL, Rodriguez-Cruz V, Ramkissoon SH, et al. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget. 2015;6:1190–1201.
   PubMedGoogle Scholar
• Zhang T, Hu Y, Ju J, et al. Downregulation of miR-522 suppress proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN/MADD domain containing 2D. Sci Rep. 2016;6:19346.
   PubMed Web of Science ®Google Scholar
• Meng L, Liu C, Lu J, et al. Small RNA zippers lock miRNA molecules and block miRNA function in mammalian cells. Nat Commun. 2017;8:13964.
   PubMed Web of Science ®Google Scholar
• Yang J, Meng X, Pan J, et al. CRISPR/Cas9-mediated noncoding RNA editing in human cancers. RNA Biol. 2018;15:35–43.
   PubMed Web of Science ®Google Scholar
• Aquino-Jarquin G. Emerging role of CRISPR/Cas9 technology for microRNAs editing in cancer research. Cancer Res. 2017;77:6812–6817.
   PubMed Web of Science ®Google Scholar
• Huo W, Zhao G, Yin J, et al. Lentiviral CRISP/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells. J Cancer. 2017;8:57–64.
   PubMed Web of Science ®Google Scholar
• Fatimy RE, Subramanian S, Uhlmann EJ, et al. Genome editing reveals glioblastoma addiction to microRNA-10b. Mol Ther. 2017;25:368–378.
   PubMed Web of Science ®Google Scholar
• Chang H, Yi B, Ma R, et al. CRISPR/Cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Sci Rep. 2016;6:22312.
   PubMed Web of Science ®Google Scholar
• Patutina OA, Bichenkova EV, Miroshnichenko SK, et al. miRNases: novel oligonucleotide-peptide bioconjugates that silence miR-21 in lymphosarcoma cells. Biomaterials. 2017;122:163–178.
   PubMed Web of Science ®Google Scholar
• Patutina OA, Bazhenov MA, Miroshnichenko SK, et al. Peptide-oligonucleotide conjugates exhibiting pyrimidine-X cleavage specificity efficiently silence miRNA target acting synergistically with RNase H. Sci Rep. 2018;8:14990.
   PubMed Web of Science ®Google Scholar
• Gaglione M, Milano G, Chambery A, et al. PNA-based artificial nucleases as antisense and anti-miRNA oligonucleotide agents. Mol Biol Syst. 2011;7:2490–2499.
   Google Scholar
• Rodrigues AC, Li X, Radecki L, et al. MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. Biopharm Drug Dispos. 2011;32:355–367.
   PubMed Web of Science ®Google Scholar
• Scott GK, Mattie MD, Berger CE, et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006;66:1277–1281.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang S, Meng F, et al. SM2miR: a database of the experimentally validated small molecule’s effects on microRNA expression. Bioinformatics. 2013;29:409–411.
   PubMed Web of Science ®Google Scholar
• Meng F, Wang J, Dai E, et al. Psmir: a database of potential associations between small molecules and miRNAs. Sci Rep. 2016;6:19264.
   PubMed Web of Science ®Google Scholar
• Biersack B. Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and prevention. Non-coding RNA Res. 2016;1:12–34.
   PubMedGoogle Scholar
• Zhang S, Chen L, Jung EJ, et al. Targeting microRNAs with small molecules: from dream to reality. Clin Pharmacol Ther. 2010;87:754–758.
   PubMed Web of Science ®Google Scholar
• Yin J, Chen X, Wang CC, et al. Prediction of small molecule-microRNA associations by sparse learning and heterogeneous graph inference. Mol Pharm. 2019;16:3157–3166. .
   Google Scholar
• Wang J, Meng F, Dai E, et al. Identification of associations between small molecule drugs and miRNAs based on functional similarity. Oncotarget. 2016;7:38658–38669.
   PubMedGoogle Scholar
• Qu J, Chen X, Sun YZ, et al. Inferring potential small molecule-miRNA association based on triple layer heterogeneous network. J Cheminform. 2018;10:30.
   PubMed Web of Science ®Google Scholar
• Qu J, Chen X, Sun YZ, et al. In silico prediction of small molecule-miRNA associations based on the HeteSim Algorithm. Mol Ther Nucleic Acids. 2019;14:274–286.
   PubMedGoogle Scholar
• Jiang W, Chen Z, Liao M, et al. Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. Sci Rep. 2012;2:282.
   PubMed Web of Science ®Google Scholar
• Treiber T, Treiber N, Plessmann U, et al. A compendium of RNA-binding proteins that regulates microRNA biogenesis. Mol Cell. 2017;66:270–284.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang F, Zubovic L, et al. Targeted inhibition of oncogenic miR-21 maturation with designed RNA-binding proteins. Nat Chem Biol. 2016;12:717–723.
   PubMed Web of Science ®Google Scholar
• Vos PD, Leedman PJ, Filipovska A, et al. Modulation of miRNA function by natural and synthetic RNA-binding proteins in cancer. Cell Mol Life Sci. 2019;76:3745–3752.
   PubMed Web of Science ®Google Scholar
• Pfeffer SR, Yang C, Pfeffer LM. The role of miR-21 in cancer. Drug Dev Res. 2015;76:270–277.
   PubMed Web of Science ®Google Scholar
• Wang W. Study of miR-10b regulatory mechanism for epithelial-mesenchymal transition, invasion and migration in nasopharyngeal carcinoma cells. Oncol Lett. 2017;14:7207–7210.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ren W, Huang B, et al. MicroRNA-183/182/96 cooperatively regulates the proliferation of colon cancer cells. Mol Med Rep. 2015;12:668–674.
   PubMed Web of Science ®Google Scholar
• Zhang R, Li F, Wang W, et al. The effect of antisense inhibitor of miRNA 106b-25 on the proliferation, invasion, migration, and apoptosis of gastric cancer cell. Tumor Biol. 2016;37:10507–10515.
   PubMedGoogle Scholar
• Li P, Sheng C, Huang L, et al. miR-183-96-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast Cancer Res. 2014;16:473.
   PubMed Web of Science ®Google Scholar
• Ma J, Zhan Y, Xu Z, et al. ZEB1 induced miR-99/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma. Cancer Lett. 2017;398:37–45.
   PubMed Web of Science ®Google Scholar
• Cao H, Yu W, Li X, et al. A new plasmid-based microRNA inhibitor system that inhibits microRNA families in transgenic mice and cells: a potential new therapeutic reagent. Gene Ther. 2016;23:527–542.
   PubMed Web of Science ®Google Scholar
• Jung J, Yeom C, Choi YS, et al. Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge. Oncotarget. 2015;6:20370–20387.
   PubMedGoogle Scholar
• Lu Y, Xiao J, Lin H, et al. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res. 2009;37:e24.
   PubMed Web of Science ®Google Scholar
• Barta T, Peskova L, Hampl A. miRNAsong: A web-based tool for generation and testing of miRNA sponge constructs in silico. Sci Rep. 2016;6:36625.
   PubMed Web of Science ®Google Scholar
• Zhou L, Jiang F, Chen X, et al. Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN. Oncol Lett. 2016;12:4419–4426.
   PubMed Web of Science ®Google Scholar
• Dylla L, Jedlicka P. Growth-promoting role of the miR-106a~363 cluster in Ewing sarcoma. PLoS One. 2013;8:e63032.
   PubMed Web of Science ®Google Scholar
• Liep J, Kilic E, Meyer HA, et al. Cooperative effect of miR-141-3p and miR-145-5-p in the regulation of targets in renal cell carcinoma. PLoS One. 2016;11:e0157801.
   PubMed Web of Science ®Google Scholar
• Kasinski AL, Kelnar K, Stahlhut C, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2014;34:3547–3555.
   PubMed Web of Science ®Google Scholar
• Feng SD, Mao Z, Liu C, et al. Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma. Oncol Targets Ther. 2017;10:5591–5604.
   PubMed Web of Science ®Google Scholar
• Orellana EA, Li C, Lisevick A, et al. Identification and validation of microRNAs that synergize with miR-34a – a basis for combinatorial microRNA therapeutics. Cell Cycle. 2019 Jul 1;1–14. DOI:10.1080/15384101.2019.1634956.
   Web of Science ®Google Scholar
• Lai X, Gupta SK, Schmitz U, et al. MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance. Theranostics. 2018;8:1106–1120.
   PubMed Web of Science ®Google Scholar
• Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467:86–90.
   PubMed Web of Science ®Google Scholar
• Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther. 2011;10:1224–1232.
   Web of Science ®Google Scholar
• Li WQ, Yu HY, Li YM, et al. Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor. Biochem Biophys Res Commun. 2014;446:1261–1267.
   PubMed Web of Science ®Google Scholar
• Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene. 2007;26:2799–2803.
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Bottai G, Nuciforo PG, et al. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget. 2015;6:37269–37280.
   PubMed Web of Science ®Google Scholar
• Frampton AE, Castellano L, Colombo T, et al. MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology. 2014;146:e18.
   Web of Science ®Google Scholar
• Bi C, Chung TH, Huang G, et al. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 2015;6:26508–26518.
   PubMedGoogle Scholar
• Ramassone A, Pagotto S, Veronese A, et al. Epigenetics and microRNAs in cancer. Int J Mol Sci. 2018;19:459.
   Google Scholar
• RH B, UK A, Weiss A, et al. Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment. Angiogenesis. 2017;20:245–267.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhu L, Zuo W, et al. MicroRNA-mediated epigenetic targeting of surviving significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. Oncotarget. 2016;7:37693–37713.
   PubMedGoogle Scholar
• To KK. MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci. 2013;20:99.
   PubMed Web of Science ®Google Scholar
• Lai X, Eberhardt M, Schmitz U, et al. Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer. Nucleic Acids Res. 2019;47:7753–7766.
   PubMed Web of Science ®Google Scholar
• Dai X, Jiang Y, Tan C. Let-7 sensitizes KRAS mutant tumor cells to chemotherapy. PLoS One. 2015;10:e0126653.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen Y, Li J, et al. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. Cancer Sci. 2017;108:1493–1503.
   PubMed Web of Science ®Google Scholar
• Chen X, Peng D, Shen Y, et al. The potential combinational effect of miR-34a with celecoxib in osteosarcoma. Anticancer Drugs. 2017;28:888–897.
   PubMed Web of Science ®Google Scholar
• Stahlhut C, Slack FJ. Combinatorial action of microRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation. Cell Cycle. 2015;14:2171–2180.
   PubMed Web of Science ®Google Scholar
• Baldassari F, Zerbinati C, Galasso M, et al. Screen for microRNA and drug interactions in breast cancer cell lines points to miR-126 as a modulator of CDK4/6 and PIK3CA inhibitors. Front Genet. 2018;9:174.
   PubMed Web of Science ®Google Scholar
• Zhou J, Lv L, Lin C, et al. Combinational treatment with microRNA-133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR. Mol Med Rep. 2015;12:5407–5414.
   PubMed Web of Science ®Google Scholar
• Zeng A, Wei Z, Yan W, et al. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Cancer Lett. 2018;436:10–21.
   PubMed Web of Science ®Google Scholar
• Chaudhary AK, Mondal G, Kumar V, et al. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Cancer Lett. 2017;402:1–8.
   PubMed Web of Science ®Google Scholar
• Mondal G, Almawash S, Chaudhary AK, et al. EGFR-targeted cationic polymeric mixed micelles for codelivery of gemcitabine and miR-205 for treating advanced pancreatic cancer. Mol Pharm. 2017;14:3121–3133.
   PubMed Web of Science ®Google Scholar
• Jiang J, Xie C, Liu Y, et al. Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27. Biomed Pharmacother. 2019;109:595–601.
   PubMed Web of Science ®Google Scholar
• Yu G, Jia B, Cheng Y, et al. MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4. Am J Transl Res. 2017;9:5048–5055.
   PubMed Web of Science ®Google Scholar
• Tan Z, Zhao J, Jiang Y. MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway. Cancer Med. 2018;7:913–921.
   PubMed Web of Science ®Google Scholar
• Tu MJ, Ho PY, Zhang QY, et al. Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. Cancer Lett. 2019;442:82–90.
   PubMed Web of Science ®Google Scholar
• Chen H, Liu L, Li X, et al. MicroRNA-1294 inhibits the proliferation and enhances the chemosensitivity of glioma to temozolomide via the direct targeting of TPX2. Am J Cancer Res. 2018;8:291–301.
   PubMed Web of Science ®Google Scholar
• Zhao J, Fu W, Liao H, et al. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer. BMC Cancer. 2015;15:731.
   PubMed Web of Science ®Google Scholar
• Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7:1–9.
   PubMed Web of Science ®Google Scholar
• Gallach S, Calabuig-Farinas S, Jantus-Lewintre E, et al. MicroRNAs: promising new antiangiogenic targets in cancer. Biomed Res Int. 2014;2014:878450.
   PubMed Web of Science ®Google Scholar
• Ji Y, Hocker JD, Gattinoni L. Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin Immunol. 2016;28:45–53.
   PubMed Web of Science ®Google Scholar
• Hand TW, Cui W, Jung YW, et al. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci USA. 2010;107:16601–16606.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang C, Li F, et al. Regulation of memory CD8+ T cell differentiation by MicroRNAs. Cell Physiol Biochem. 2018;47:2187–2198.
   PubMedGoogle Scholar
• Ohno M, Ohkuri T, Kosaka A, et al. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer. 2013;1:21.
   PubMedGoogle Scholar
• Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25:4066–4074.
   PubMed Web of Science ®Google Scholar
• Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012;12:801–817.
   PubMed Web of Science ®Google Scholar
• LC H, BJ S, HMW V, et al. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis. 2017;20:217–232.
   PubMed Web of Science ®Google Scholar
• Wang S, Olson EN. AngiomiRs – key regulators of angiogenesis. Curr Opin Genet Dev. 2009;19:205–211.
   PubMed Web of Science ®Google Scholar
• Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Boil. 2007;27:1859–1867.
   PubMed Web of Science ®Google Scholar
• Babar IA, Czochor J, Steinmetz A, et al. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther. 2011;12:908–914.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun L. Knockdown of LMP1-induced miR-155 sensitizes nasopharyngeal carcinoma cells to radiotherapy in vitro. Oncol Lett. 2016;11:3451–3456.
   PubMed Web of Science ®Google Scholar
• Cortez MA, Valdecanas D, Niknam S, et al. In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation. Mol Ther Nucleic Acids. 2015;4:e270.
   PubMedGoogle Scholar
• Ma W, Ma C, Zhou N, et al. Up-regulation of miR-328-3p sensitizes non-small cell lung cancer to radiotherapy. Sci Rep. 2016;6:31651.
   PubMed Web of Science ®Google Scholar
• Kessel D, Oleinick NL. Cell death pathways associated with photodynamic therapy: an update. Photochem Photobiol. 2018;94:213–218.
   PubMed Web of Science ®Google Scholar
• Rumie Vittar NB, Lamberti MJ, Panasa MF, et al. Ecological photodynamic therapy: new trend to disrupt the intricate networks within tumor ecosystem. Biochim Biophys Acta. 2013;1835:86–99.
   PubMed Web of Science ®Google Scholar
• Bach D, Fuereder J, Karbiener M, et al. Comprehensive analysis of alternations in the miRNome in response to photodynamic treatment. J Photochem Photobiol B. 2013;120:74–81.
   PubMed Web of Science ®Google Scholar
• Chakrabarti M, Banik NL, Ray SK. Photofrin based photodynamic therapy and miR-99a transfection inhibited FGFR3 and PI3K/AKT signaling mechanisms to control growth of human glioblastoma in vitro and in vivo. PLoS ONE. 2013;8:e55652.
   PubMed Web of Science ®Google Scholar
• Passadouro M, Faneca H. Combination of anti-miRNAs oligonucleotides with low amounts of chemotherapeutic agents for pancreatic cancer therapy. Methods Mol Biol. 2018;1699:135–154.
   PubMedGoogle Scholar
• Passadouro M, Pedroso de Lima MC, Faneca H. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer. Int J Nanomedicine. 2014;9:3203–3217.
   PubMed Web of Science ®Google Scholar
• Li CH, Xiao Z, Tong JH, et al. EZH2 coupled with HOTAIR to silence microRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma. Int J Cancer. 2017;140:120–129.
   PubMed Web of Science ®Google Scholar
• Hajjari M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med. 2015;12:1–9.
   PubMed Web of Science ®Google Scholar
• Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008;68:8164–8172.
   PubMed Web of Science ®Google Scholar
• Karsy M, Arslan E, Moy D. Current progress on understanding microRNAs in glioblastoma multiforme. Genes Cancer. 2012;3:3–15.
   PubMedGoogle Scholar
• Mathupala SP, Guthikonda M, Sloan AE. RNAi based approaches to the treatment of malignant glioma. Technol Cancer Res Treat. 2006;5:261–269.
   PubMed Web of Science ®Google Scholar
• Malhotra M, Sekar TV, Ananta JS, et al. Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model. Oncotarget. 2018;9:21478–21494.
   PubMedGoogle Scholar
• Nadaradjane A, Briand J, Bougras-Cartron G, et al. miR-370-3p is a therapeutic tool in anti-glioblastoma therapy but is not an intratumoral or cell-free circulating biomarker. Mol Ther Nucleic Acids. 2018;13:642–650.
   PubMedGoogle Scholar
• Nie E, Jin X, Wu W, et al. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. J Neurooncol. 2017;133:59–68.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li R, Pan M, et al. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. J Neuro-Oncol. 2017;133:477–485.
   PubMed Web of Science ®Google Scholar
• Ramachandran M, Yu D, Dyczynski M, et al. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically delivered triple microRNA-detargeted oncolytic Semliki Forest Virus. Clin Cancer Res. 2017;23:1519–1530.
   PubMed Web of Science ®Google Scholar
• Bhaskaran V, Nowicki MO, Idriss M, et al. The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. Nat Commun. 2019;10:442.
   PubMed Web of Science ®Google Scholar
• Wallace JA, O’Connell RM. MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts. Blood. 2017;139:1290–1301.
   Google Scholar
• Huang X, Schwing S, Yu B, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res. 2013;19:2355–2367.
   PubMed Web of Science ®Google Scholar
• Lu F, Zhang J, Ji M, et al. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol. 2014;45:383–392.
   PubMed Web of Science ®Google Scholar
• Shah NM, Zaitseva L, Bowles KM, et al. NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. Cell Death Differ. 2015;22:654–664.
   PubMed Web of Science ®Google Scholar
• Khalife J, Radomska HS, Santhanam R, et al. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia. 2015;29:1981–1992.
   PubMed Web of Science ®Google Scholar
• Chen P, Price C, Li Z, et al. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci USA. 2013;110:11511–11516.
   PubMed Web of Science ®Google Scholar
• Emmrich S, Katsman-Kuipers JE, Henke K, et al. miR-9 is a tumor suppressor in pediatric AML with t(8;21). Leukemia. 2014;28:1022–1032.
   PubMed Web of Science ®Google Scholar
• Senyuk V, Zhang Y, Liu Y, et al. Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis. Proc Natl Acad Sci USA. 2013;110:5594–5599.
   PubMed Web of Science ®Google Scholar
• Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a-mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35:180–188.
   PubMed Web of Science ®Google Scholar
• Van Zandwijk N, Pavlakis N, Kao SC, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386–1396.
   PubMed Web of Science ®Google Scholar
• Qi Y, Huang Y, Pang L, et al. Prognostic value of the microRNA-29 family in multiple human cancers: a meta-analysis and systematic review. Clin Exp Pharmacol Physiol. 2017;44:441–454.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128–141.
   PubMed Web of Science ®Google Scholar
• Labatut AE, Mattheolabakis G. Non-viral based miR delivery and recent developments. Eur J Pharm Biopharm. 2018;128:82–90.
   PubMed Web of Science ®Google Scholar
• Collins SA, Guinn BA, Harrison PT, et al. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther. 2008;8:66–78.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen H, Shi J. Inorganic nanoparticle-based drug codelivery nanosystems to overcome the multidrug resistance of cancer cells. Mol Pharm. 2014;11:2495–2510.
   PubMed Web of Science ®Google Scholar
• Campani V, Salzano G, Lusa S, et al. Lipid nanovectors to deliver RNA oligonucleotides in cancer. Nanomaterials (Basel). 2016;6(7):E131.
   PubMedGoogle Scholar
• Ando H, Okamoto A, Yokota M, et al. Polycation liposomes as a vector for potential intracellular delivery of microRNA. J Gene Med. 2013;15:375–383.
   PubMed Web of Science ®Google Scholar
• Qian X, Long L, Shi Z, et al. Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma. Biomaterials. 2014;35:2322–2335.
   PubMed Web of Science ®Google Scholar
• Dai Y, Zhang X. MicroRNA delivery with bioreducible polyethylenimine as a non-viral vector for breast cancer gene therapy. Macromol Biosci. 2019;19:e1800445.
   PubMed Web of Science ®Google Scholar
• Li Y, Dai Y, Zhang X, et al. Three-layered polyplex as a microRNA targeted delivery system for breast cancer gene therapy. Nanotechnology. 2017;28:285101.
   PubMed Web of Science ®Google Scholar
• Yin PT, Pongkulapa T, Cho HY, et al. Overcoming chemoresistance in cancer via combined microRNA therapeutics with anticancer drugs using multifunctional magnetic core-shell nanoparticles. ACS Appl Mater Interfaces. 2018;10:26954–26963.
   PubMed Web of Science ®Google Scholar
• Huang Y. Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics. Mol Ther Nucleic Acids. 2017;6:116–132.
   PubMedGoogle Scholar
• Van der Ree M, de Vree ML, Stelma F, et al. A single subcutaneous dose of 2mg/kg or 4mg/kg of RG-101, a GalAc-conjugated oligonucleotide with antagonist activity against miR-122, results in significant viral load reductions in chronic hepatitis C patients. J Hepatol. 2015;62:S261.
   Web of Science ®Google Scholar
• Wang X, Xiao X, Zhang B, et al. A self-assembled peptide nucleic acid-microRNA nanocomplex for dual modulation of cancer-related microRNAs. Chem Commun. 2019;55:2106.
   PubMed Web of Science ®Google Scholar
• Ashley CE, Carnes EC, Phillips GK, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater. 2011;10:389–397.
   PubMed Web of Science ®Google Scholar
• Park K, Lee MY, Kim KS, et al. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials. 2010;31:5258–5265.
   PubMed Web of Science ®Google Scholar
• Ito T, Iida-Tanaka N, Niidome T, et al. Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. J Control Release. 2006;112:382–388.
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang L, Bai X, et al. Stimuli-responsive nanocarrier for co-delivery of miR-31 and doxorubicin to suppress high MtEF4 cancer. ACS Appl Mater Interfaces. 2018;10:22767–22775.
   PubMed Web of Science ®Google Scholar
• Wang W, Chen L, Xu LP, et al. A free-blockage controlled release system based on the hydrophobic/hydrophilic conversion of mesoporous silica nanopores. Chemistry. 2015;21:2680–2685.
   PubMed Web of Science ®Google Scholar
• Uz M, Kalaga M, Pothuraju R, et al. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer. J Control Release. 2019;294:237–246.
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136–151.
   PubMed Web of Science ®Google Scholar
• Yin H, Wang H, Li Z, et al. RNA micelles for the systemic delivery of anti-miRNA for cancer targeting and inhibition without ligand. ACS Nano. 2019;13:706–717.
   PubMed Web of Science ®Google Scholar
• Yao C, Liu J, Wu X, et al. Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy. J Control Release. 2016;232:203–214.
   PubMed Web of Science ®Google Scholar
• Xie Y, Chen Y, Sun M, et al. A mini review of biodegradable calcium phosphate nanoparticles for gene delivery. Curr Pharm Biotechnol. 2013;14:918–925.
   PubMed Web of Science ®Google Scholar
• Jung H, Kim SA, Yang YG, et al. Long chain microRNA conjugates in calcium phosphate nanoparticles for efficient formulation and delivery. Arch Pharm Res. 2015;38:705–715.
   PubMed Web of Science ®Google Scholar
• Chulpanova DS, Kitaeva KV, James V, et al. Therapeutic prospects of extracellular vesicles in cancer treatment. Front Immunol. 2018;9:1534.
   PubMed Web of Science ®Google Scholar
• Almanza G, Rodvold JJ, Tsui B, et al. Extracellular vesicles produced in B cells deliver tumor suppressor miR-335 to breast cancer cells disrupting oncogenic programming in vitro and in vivo. Sci Rep. 2018;8:17581.
   PubMed Web of Science ®Google Scholar
• Usman WM, Pham TC, Kwok YY, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9:2359.
   PubMed Web of Science ®Google Scholar
• Torrano V, Rovo F, Peinado H, et al. Vesicle-MaNia: extracellular vesicles in liquid biopsy and cancer. Curr Opin Pharmacol. 2016;29:47–53.
   PubMed Web of Science ®Google Scholar
• Allen AG, Chung CH, Atkins A, et al. Gene editing of HIV-1 co-receptors to prevent and/or cure virus infection. Front Microbiol. 2018;9:2940.
   PubMed Web of Science ®Google Scholar
• Ooi JYY, Bernardo BC, Singla S, et al. Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: implications for treating cardiac pathology and other diseases. RNA Biol. 2017;14:500–513.
   PubMed Web of Science ®Google Scholar
• Jin JY, Gonzalez-Martin A, Miletic AV, et al. Transfection of microRNA mimics should be used with caution. Front Genet. 2015;6:340.
   PubMed Web of Science ®Google Scholar
• Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129:1401–1414.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Ivan M, Cimmino A, et al. Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 2007;7:1009–1019.
   PubMed Web of Science ®Google Scholar